Abstract
INTRODUCTION
Immunoglobulin light chain (AL) amyloidosis is a syste mic plasma cell disorder, characterized by the pro duction of a kappa or lambda monoclonal light chain by a clonal population of bone marrow plasma cells [1] . The monoclonal light chain misfolds into an insoluble betapleated sheet conformation. The aberrant protein subsequently accumulates in tissues, leading to organ dysfunction.
Cardiac involvement occurs in 50% of patients with systemic AL amyloidosis and is the most important risk factor for adverse prognosis and death [2, 3] . Amyloid fibrils infiltrate the extracellular space of the valves, atria and ventricles, as well as the perivascular spaces, resulting in biventricular wall thickening without ventricular dila tion [4] . As a result, atrial pressure increases, and atrial dilation occurs despite amyloid infiltration. Clinical fea tures of cardiac amyloidosis include restrictive physio logy, heart failure, dysrhythmias, and sudden cardiac death [1, 4, 5] . In addition, there is evidence suggesting that the immunoglobulin free light chains are toxic to the myocardium [6] . Patients with advanced heart failure due to AL have an extremely poor prognosis and often do not survive long enough to benefit from therapy for amyloidosis. Orthotopic heart transplantation (OHT) in AL has been limited due to the risk of disease progression in other organs and recurrence of amyloid deposition in the transplanted heart [7, 8] . Although earlier studies suggested inferior outcomes of OHT for compared with nonamyloid indications [8, 9] , more recent reports have found survival similar to other forms of heart failure [10] . Controversy regarding the role of OHT in AL remains [11, 12] and many centers consider amyloidosis to be a contraindication to OHT. The purpose of the current study was to determine the long term outcome and predictors of survival in a large singlecenter cohort of patients undergoing OHT for AL.
MATERIALS AND METHODS

Study population
Patients were identified from our institutional database of cardiac transplantation recipients. The diagnosis of amyloidosis was confirmed by demonstrating Congo red positivity in tissue samples. AL amyloid was confirmed by laser dissection mass spectrometry in all but two patients, who had typing performed by immunohistochemistry. During the period from May 31, 1992 to December 31, 2011, 3117 patients with AL amyloidosis were seen at the Mayo Clinic. Twenty one percent (668 patients) had overt congestive heart failure. One hundred and thirtyseven were referred for OHT evaluation, and 77 patients completed their evaluation for OHT. Of those completing the evaluation, 33 were deemed ineligible for OHT. Reasons for ineligibility included extensive amyloid in 29 and one instance of each of the following: Coexisting myeloma; coexisting lymphoma; improving cardiac status due to chemotherapy; and lack of financial approval. Forty four patients (7% of patients with overt heart failure) completed evaluation and were listed for OHT, but only 23 were transplanted. Twentyone were removed from the listing for the following reasons: Death (n = 12); further medical decline (n = 5); patient refusal (n = 2); myeloma (n = 1); and transplant elsewhere (n = 1). The median time to delisting was 48 d (interquartile range 14, 111 d; range 0341 d).
Throughout the 20year period, all patients met at least one of the following at time of listing: New York Heart Association class Ⅳ heart failure, ventricular thickness > 15 mm, ejection fraction < 40%. In 1998, additional selection guidelines were added: Age < 60 years; combination of the urine light chain, serum monoclonal protein and bone marrow plasmacytosis that does not infer the presence of multiple myeloma or related disorders including low bone marrow plasma cell labeling index; absence of renal involvement as defined by a 24h urine total protein excretion of < 500 mg and creatinine clearance > 50 mL/min per square meter unless combined renal transplant planned; absence of liver involvement if elevation of alkaline phosphatase was thought to be due to heart failure, liver biopsy was to be done to exclude interstitial amyloid deposits. The presence of vascular deposits in a biopsy of the rectum, fat or viscera was not an exclusionary criterion. Assignment of organ involvement was according to the consensus criteria from the 10 th International
Symposium on Amyloid and Amyloidosis [13] . The modi fied body mass index (mBMI) was calculated as BMI multiplied by serum albumin level in gram per litre. For most patients the values used for listing and pre operative BMI (and mBMI) were the same given the proximity of listing to OHT.
The autologous hematopoietic stem cell trans plantation (AHSCT) protocol is as previously described, and 11 of the patients have been previously reported [14] . Demographic, clinical and laboratory data were collected from the Mayo Clinic Transplant Center database, the Robert A Kyle Dysproteinemia database, and all medical records were reviewed. Because most of these patients were treated before era of the serum immunoglobulin free light chain assay, the ability to assign a hematologic response was limited. The determination of hematologic response was a hybrid of the two consensus guidelines. If patients had serum immunoglobulin free light chains measured (n = 9), then the 2012 consensus response criteria were applied [15] ; otherwise, the 10 th consensus response criteria from the International Symposium on Amyloid and Amyloidosis were applied [13] . Two patients had measurable Mspikes, 8 had positive immu nofixation of the serum or urine that could be followed, and 4 either had none of the aforementioned detected (or testing not performed prior to starting chemo therapy).
Immunosuppression
Post OHT, all patients received standard therapy for immunosuppression, according to our institutional protocol at the time of transplant. The first twentyone patients received OKT3, cyclosporine, prednisone, and azathioprine or mycophenate mofetil. A gradual taper of cyclosporine was done over the first year to baseline immunosuppression. Surveillance endomyocardial biopsies to monitor for rejection were used to help guide prednisone taper. The last two patients received prednisone, mycophenate mofetil, and tacrolimus.
Statistical analysis
Medical records for the patients undergoing OHT for AL amyloidosis were reviewed. Survival from the time of OHT was calculated using KaplanMeier survival curves.
Comparison of survival curves was done with the log rank test. Baseline variables were tested for their impact on overall survival using Cox proportional modeling. The database was closed to follow up as of March 18, 2015. All statistics were calculated using JMP 10.0.0 (SAS, Carey, North Carolina).
RESULTS
Twentythree patients with AL amyloidosis underwent OHT (Table 1) . Fiftytwo percent were female (n = 12), and all but two were Caucasian. Twentyone patients had isolated cardiac involvement at baseline clinical evaluation; one patient (OHT#14) had mild peripheral nerve and gastrointestinal involvement, and one (OHT #15) had peripheral nerve involvement. Twentytwo patients had had a clonal lambda plasma cell disorder; one had a kappa clone. Three patients had renal transplantation, one simultaneous with the OHT and the others at 23 and 53 mo post OHT. Twenty patients have died post OHT (Table 1 and Figure 1A ). The baseline disease burden is outlined in Table 2 . For the entire cohort, the median overall survival was 3.5 years (95%CI: 1.2, 8.2 years). The 1year survival post OHT was 77%, the 2year survival 65%, and the 5year survival 43% ( Figure 1A ). Progressive amyloidosis contributed to death in twelve patients. Of those without evidence of progressive amyloidosis, the cause of death included postAHSCT complications for 3 patients, posttransplant lymphoproliferative disorder for 2 patients; and for the remaining there was one death related to each of the following causes: Acute rejection; cardiac vasculopathy; metastatic melanoma; myelodysplastic syndrome; and unknown. Eight patients had rejection at a median of 1.8 mo post OHT (range 0.4 to 4.9 mo); only one patient died of rejection). Grogan M et al . Grogan, cardiac transplant in AL Figure 1B shows a comparison of this cohort to patients undergoing isolated OHT at our center for non amyloid indications, where 1 year overall survival is 94.8% ± 2.1% and 5year survival 85.2% ± 4.4%. Given the small sample size, it is difficult to assess baseline factors that might predict for early death. Notably, no patient died within the immediate OHT perioperative period. On univariate analysis none of the following factors were significant risk factors for poor overall survival: Age, gender, BMI or mBMI (at listing or at transplant), time from listing to OHT, serum creatinine, or bone marrow plasmacytosis. Figure 1C shows the comparison of patients with AL who underwent OHT with AL patients without and with overt heart failure who did not undergo OHT, and with those who were listed but did undergo OHT.
Three patients had no therapy (chemotherapy or AHSCT) for amyloidosis and only four received treatment prior to OHT (Table 3) . Reasons for no chemotherapy/ AHSCT were: Inability to harvest stem cells for planned AHSCT; rejection two weeks after OHT; and death 7 mo after OHT. One patient received chemotherapy only prior to OHT, 4 received chemotherapy pre and post OHT, and 15 only postOHT. The nonAHSCT first line therapies are shown in Table 3 . Therapies beyond first line therapies included bortezomib, AHSCT, melphalan with corticosteroids, or an IMiD with dexamethasone; one patient received doxorubicin.
After their first line therapy, seven patients achieved a complete hematologic response (CR), 3 a very good partial response, 2 a partial response, and 11 remained immunofixation positive or were not assessed before death (Table 3) . As shown in Figure 2A , patients achieving a CR fared much better than those who did not, achieving a median survival of 10.8 years.
Thirteen patients underwent AHSCT, performed at a median of 8 mo (range 324 mo) post OHT with one patient having a second AHSCT 82 mo post OHT. In two patients AHSCT was planned but could not be performed due to inability to harvest stem cells. The median survival of those undergoing AHSCT was 6.3 years (95%CI: 1.2, 8.6 years). Figure 2B 
DISCUSSION
Given the limited supply of donor hearts, OHT in AL amyloidosis remains controversial due to the risk of recurrent amyloidosis in the graft or progression of other organ involvement. This long term followup study reports the largest single center experience of OHT in AL. Our results support the use of OHT in AL amyloidosis patients with predominant cardiac involvement and no evidence of myeloma, especially if they have achieved (or are able to achieve) a complete hematologic response.
Although the median overall survival of our cohort was only 3.5 years, those patients who achieved a complete hematologic response had a remarkably good overall median survival of more than 10 years. Superior survival is reported in patients with AL amyloidosis and cardiac involvement who undergo OHT compared to patients who do not [14, 16] . In a report of 14 patients from the United Kingdom, median overall survival was 7.5 years from OHT; in 8 patients who underwent AHSCT and OHT, survival was increased to 9.7 years [17] . These data are confounded by selection biases, but the fact remains that 30%40% of patients with AL amyloidosis die within the first 6 mo of their diagnosis due to cardiac causes [18] making consideration of aggressive strategies imperative. Most series of heart transplantation in AL have reasonable 1year survival rates (Table 4 ). In our study there was no perioperative mortality. The major causes of death in our and other series are infection and progressive amyloidosis. If performed without chemo therapeutic support, 5year survival is just 20% [19] , Improved survival rates have been seen in patients who undergo AHSCT, with 1 and 5year survival of 82% and 65% respectively in our earlier report [14] . Recent reports suggest improved short term outcomes with advances in chemotherapy and AHSCT, with the Stanford series reporting 1 year survival of 100% [20] . In the MGH series of 18 AL patients undergoing OHT approximately 60% of patients were alive at 6 years [10] , and, in contrast to earlier studies [8, 9, 21] , was similar to that of nonamyloid patients. Although overall survival in our study was reduced compared with patients transplanted for nonamyloid indications, our series includes many early era patients who did not receive the benefit of current therapy for amyloidosis. Nevertheless, the long term survival of the patients in our series who achieved complete hematologic response was remarkably good.
Selecting patients with primarily cardiac involvement in AL is challenging. Subclinical extracardiac organ involvement may progress post heart transplant to clinically important disease. Perivascular intestinal amyloid is common and not viewed as a barrier to cardiac transplantation. However, in our experience, patients with significant mucosal intestinal involvement do poorly and are often not able to tolerate aggressive treatment for AL. Clearly not all patients with cardiac involvement will require heart transplant; there are patients with significant cardiac involvement who can have cardiac improvement with effective chemotherapy alone [2225] . Perhaps cardiac biomarkers like ST2 may lend insight to those with irreparable damage despite effective chemotherapy [26] . "Better selection" also means choosing those patients in whom the underlying plasma cell clone can be controlled, since in our study and others effective chemotherapy has resulted in the best outcomes post OHT [10, 16, 20] . Most of the patients in our series did not receive chemotherapy prior to OHT because the only chemotherapies available at the time of their diagnosis were oral melphalan and prednisone and high dose melphalan with AHSCT. Newer treatment options [27] , especially bortezomib containing regimens, are less myelosuppressive, making preOHT therapy a possibility. Furthermore, the improvement in chemotherapeutic regimens makes hematologic response more likely in the current era.
Achieving a hematologic response preOHT is not a simple matter. Time is of the essence in these patients. In our experience and others, approximately 40% of AL patients listed do not undergo OHT either due to death or deterioration [10] . This seems to be related to both delayed diagnosis, as well as inability to support these patients with traditional heart failure therapy and devices. In the MGH series, patients with amyloidosis had a mortality hazard ratio of 4.7 (95%CI: 2.8, 11.8) as compared to nonamyloidosis patients while on the waiting list [10] . The only predictive factor of survival to OHT in that study was BMI patients with lower BMI fared better than those with higher BMI, although this was not confirmed in our study.
The number of AL amyloid patients transplanted at our institution in recent years has declined. This reduction is multifactorial, and reflects patients receiving earlier and more effective bone marrow directed treatment, more rigorous selection, the availability of OHT for AL at other medical centers, and our own reluc tance to offer OHT after some discouraging outcomes. However, the excellent long term survival in this study of patients achieving CR , coupled with markedly improved short term survival recently reported [20] have prompted renewed enthusiasm for OHT in AL in highly selected patients. We recognize that our study is limited by being a small series of highly selected patients, lacking currently available cardiac biomarkers and modern markers of clonal burden and access to current treatment regimens. Despite these limitations, in carefully selected patients, long term survival can be achieved. Moving forward the challenge will continue to be the selection of the appropriate patients. The patients likely to derive the most benefit are those who: (1) have plasma cells that are responsive to chemotherapy; (2) have clinically significant involvement of the heart only; and (3) are 
COMMENTS
Background
Cardiac involvement is present in approximately 50% of patients with immunoglobulin light chain (AL) amyloidosis amyloidosis and is associated with a dismal prognosis. Heart transplant for AL amyloid is controversial, due to concerns about amyloid deposition in the transplanted heart and the potential for increased morbidity and mortality from the underlying plasma cell disorder.
Research frontiers
The research goal was to review a single center experience with cardiac transplantation for AL amyloid and determine outcome.
Innovations and breakthroughs
This study demonstrates that long term survival is possible in highly selected patients with AL amyloid who undergo cardiac transplantation if the underlying plasma cell disorder can be controlled.
Applications
Patients with cardiac AL amyloid and limited extra cardiac involvement may be considered for cardiac transplantation. Long term survival is possible in those who achieve a complete hematologic response to chemotherapy or autologous stem cell transplantation.
Terminology
Immunoglobulin light chain AL is a plasma cell disorder which results in deposition of amyloid fibrils in the organs and tissues of the body. Autologous hematopoietic stem cell transplantation is a strategy to treat the underlying plasma cell disorder that causes AL amyloidosis.
